Erratum: Bcl-2 Regulates HIF-1α Protein Stabilization in Hypoxic Melanoma Cells via the Molecular Chaperone HSP90 (PLoS ONE (2010) 5:7 (e11772) DOI: 10.1371/journal.pone.0011772);Bcl-2 regulates HIF-1α protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90

PLoS ONE

Volumn 5, Issue 7, 2010, Pages 1-13

  Trisciuoglio, Daniela ^a   Gabellini, Chiara ^a,b   Desideri, Marianna ^a   Ziparo, Elio ^b   Zupi, Gabriella ^a   del Bufalo, Donatella ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; EPIDERMAL GROWTH FACTOR; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90ALPHA; HEAT SHOCK PROTEIN 90BETA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN; PROTEIN BCL 2; UBIQUITIN; UNCLASSIFIED DRUG; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; BENZOQUINONE DERIVATIVE; HIF1A PROTEIN, HUMAN; ISOPROTEIN; MACROCYCLIC LACTAM; TANESPIMYCIN;

ARTICLE; CANCER CELL CULTURE; CELL DENSITY; CELL HYPOXIA; CELL NUCLEUS; COMPLEX FORMATION; CONTROLLED STUDY; DEGRADATION KINETICS; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYDROXYLATION; MELANOMA CELL; OXYGEN TENSION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN SYNTHESIS; UBIQUITINATION; CONFOCAL MICROSCOPY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOPRECIPITATION; MELANOMA; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; TUMOR CELL LINE; WESTERN BLOTTING;

BENZOQUINONES; BLOTTING, WESTERN; CELL HYPOXIA; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOPRECIPITATION; LACTAMS, MACROCYCLIC; MELANOMA; MICROSCOPY, CONFOCAL; PROTEIN BINDING; PROTEIN ISOFORMS; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-BCL-2; UBIQUITIN;

EID: 77955606618     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0268235     Document Type: Erratum

References (45)

1. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
2. Liu YV, Baek JH, Zhang H, Diez R, Cole RN, et al. (2007) RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell 25: 207-217.
3. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, et al. (2002) Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111: 709-720.
4. Cho H, Ahn DR, Park H, Yang EG (2007) Modulation of p300 binding by posttranslational modifications of the C-terminal activation domain of hypoxiainducible factor-1alpha. FEBS Lett 581: 1542-1548.
5. Bilton R, Trottier E, Pouyssegur J, Brahimi-Horn MC (2006) ARDent about acetylation and deacetylation in hypoxia signalling. Trends Cell Biol 16: 616-621.
6. Xenaki G, Ontikatze T, Rajendran R, Stratford IJ, Dive C, et al. (2008) PCAF is an HIF-1alpha cofactor that regulates p53 transcriptional activity in hypoxia. Oncogene 27: 5785-5796.
7. Cheng J, Kang X, Zhang S, Yeh ET (2007) SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell 131: 584-595.
8. Gorlach A, Bonello S (2008) The cross-talk between NF-kappaB and HIF-1: further evidence for a significant liaison. Biochem J 412: e17-e19.
9. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, et al. (2008) NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-kalpha. Nature 453: 807-811.
10. van UP, Kenneth NS, Rocha S (2008) Regulation of hypoxia-inducible factor- 1alpha by NF-kappaB. Biochem J 412: 477-484.
11. Kaelin WG, Jr. (2008) The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8: 865-873.
12. Iervolino A, Trisciuoglio D, Ribatti D, Candiloro A, Biroccio A, et al. (2002) Bcl- 2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J 16: 1453-1455.
13. Biroccio A, Candiloro A, Mottolese M, Sapora O, Albini A, et al. (2000) Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line. FASEB J 14: 652-660.
14. Del Bufalo D, Trisciuoglio D, Scarsella M, Zangemeister-Wittke U, Zupi G (2003) Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. Oncogene 22: 8441-8447.
15. el Bufalo D, Biroccio A, Leonetti C, Zupi G (1997) Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line. FASEB J 11: 947-953.
16. Trisciuoglio D, Desideri M, Ciuffreda L, Mottolese M, Ribatti D, et al. (2005) Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth. J Cell Physiol 205: 414-421.
17. Diensthuber M, Potinius M, Rodt T, Stan AC, Welkoborsky HJ, et al. (2008) Expression of bcl-2 is associated with microvessel density in olfactory neuroblastoma. J Neurooncol 89: 131-139.
18. Trisciuoglio D, Iervolino A, Zupi G, Del Bufalo D (2005) Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells. Mol Biol Cell 16: 4153-4162.
19. Brahimi-Horn MC, Pouyssegur J (2009) HIF at a glance. J Cell Sci 122: 1055-1057.
20. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ (1990) Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336.
21. Jin Z, May WS, Gao F, Flagg T, Deng X (2006) Bcl2 suppresses DNA repair by enhancing c-Myc transcriptional activity. J Biol Chem 281: 14446-14456.
22. Portier BP, Taglialatela G (2006) Bcl-2 localized at the nuclear compartment induces apoptosis after transient overexpression. J Biol Chem 281: 40493-40502.
23. Massaad CA, Portier BP, Taglialatela G (2004) Inhibition of transcription factor activity by nuclear compartment-associated Bcl-2. J Biol Chem 279: 54470-54478.
24. Hoetelmans RW (2004) Nuclear partners of Bcl-2: Bax and PML. DNA Cell Biol 23: 351-354.
25. Baek JH, Mahon PC, Oh J, Kelly B, Krishnamachary B, et al. (2005) OS-9 interacts with hypoxia-inducible factor 1alpha and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1alpha. Mol Cell 17: 503-512.
26. D'Angelo G, Duplan E, Boyer N, Vigne P, Frelin C (2003) Hypoxia up-regulates prolyl hydroxylase activity: a feedback mechanism that limits HIF-1 responses during reoxygenation. J Biol Chem 278: 38183-38187.
27. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, et al. (2003) HIF prolylhydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 22: 4082-4090.
28. Sreedhar AS, Kalmar E, Csermely P, Shen YF (2004) Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 562: 11-15.
29. Wu X, Wanders A, Wardega P, Tinge B, Gedda L, et al. (2009) Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin. Br J Cancer 100: 334-343.
30. Levine B, Sinha S, Kroemer G (2008) Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy 4: 600-606.
31. Heath-Engel HM, Chang NC, Shore GC (2008) The endoplasmic reticulum in apoptosis and autophagy: role of the BCL-2 protein family. Oncogene 27: 6419-6433.
32. Del Bufalo D, Biroccio A, Trisciuoglio D, Bruno T, Floridi A, et al. (2002) Bcl-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug used. Eur J Cancer 38: 2455-2462.
33. Nor JE, Christensen J, Liu J, Peters M, Mooney DJ, et al. (2001) Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 61: 2183-2188.
34. Karl E, Zhang Z, Dong Z, Neiva KG, Soengas MS, et al. (2007) Unidirectional crosstalk between Bcl-xL and Bcl-2 enhances the angiogenic phenotype of endothelial cells. Cell Death Differ 14: 1657-1666.
35. Feng Z, Porter AG (1999) NF-kappaB/Rel proteins are required for neuronal differentiation of SH-SY5Y neuroblastoma cells. J Biol Chem 274: 30341-30344.
36. Ricca A, Biroccio A, Del Bufalo D, Macka AR, Santoni A, et al. (2000) bcl-2 over-expression enhances NF-kappaB activity and induces mmp-9 transcription in human MCF7(ADR) breast-cancer cells. Int J Cancer 86: 188-196.
37. Neckers L (2006) Chaperoning oncogenes: Hsp90 as a target of geldanamycin. Handb Exp Pharmacol. pp 259-277.
38. Katschinski DM, Le L, Schindler SG, Thomas T, Voss AK, et al. (2004) Interaction of the PAS B domain with HSP90 accelerates hypoxia-inducible factor-1alpha stabilization. Cell Physiol Biochem 14: 351-360.
39. Dias S, Shmelkov SV, Lam G, Rafii S (2002) VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 99: 2532-2540.
40. Kuo CC, Liang CM, Lai CY, Liang SM (2007) Involvement of heat shock protein (Hsp)90 beta but not Hsp90 alpha in antiapoptotic effect of CpG-B oligodeoxynucleotide. J Immunol 178: 6100-6108.
41. van de Sluis B, Groot AJ, Vermeulen J, van der WE, van Diest PJ, et al. (2009) COMMD1 Promotes pVHL and O2-Independent Proteolysis of HIF-1alpha via HSP90/70. PLoS One 4: e7332.
42. Zhang D, Li J, Costa M, Gao J, Huang C (2010) JNK1 mediates degradation HIF-1alpha by a VHL-independent mechanism that involves the chaperones Hsp90/Hsp70 1. Cancer Res 70: 813-823.
43. Luo W, Zhong J, Chang R, Hu H, Pandey A, et al. (2009) HSP70 and CHIP selectively mediate Ubiquitination and degradation of hypoxia-inducible factor (HIF)-1{alpha} but not HIF-2{alpha}. J Biol Chem.
44. Giorgini S, Trisciuoglio D, Gabellini C, Desideri M, Castellini L, et al. (2007) Modulation of bcl-xL in tumor cells regulates angiogenesis through CXCL8 expression. Mol Cancer Res 5: 761-771.
45. Del Bufalo D, Rizzo A, Trisciuoglio D, Cardinali G, Torrisi MR, et al. (2005) Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function. Cell Death Differ 12: 1429-1438.